Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (47)

I-05Malte Selch Larsen

Impact of trial designs, study conditions and statistical methods on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors

Wednesday 10:10-11:40

I-17Felix Stader

A population database for elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parameters

Wednesday 10:10-11:40

I-21Sabine Stuebler

Systems biology model of the mucosal immune system in the context of inflammatory bowel disease

Wednesday 10:10-11:40

I-46Tamara van Steeg

Development of a mathematical model to elucidate the cross-linking of GSK-057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality.

Wednesday 10:10-11:40

I-47Rob van Wijk

Nanoscale blood sampling from zebrafish larvae for the estimation of distribution volume and absolute clearance

Wednesday 10:10-11:40

I-49Diego Vera-Yunca

Disease modelling of repeated acute attacks in an acute intermittent porphyria mouse model

Wednesday 10:10-11:40

I-55Roeland Wasmann

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies

Wednesday 10:10-11:40

I-69Jurij Aguiar Zdovc

The expression of ABCB1 gene influences the PK of rivaroxaban – a PK/PD study in patients with the total hip or knee arthroplasty

Wednesday 10:10-11:40

I-71Ying Zhang

Exposure–Response Model and Development of a Shiny App of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients with Hereditary Angioedema (HAE)

Wednesday 10:10-11:40

I-74Li Zhang

Mechanism-based Population PK/PD modeling of T lymphocytes Depletion and Repopulation Following Treatment with anti-CD52 Antibody GLD52 in Patients with Progressive Multiple Sclerosis

Wednesday 10:10-11:40

II-04Ruben Faelens

Benefits of TDM in clinical management: a test case in infliximab for ulcerative colitis

Wednesday 15:50-17:20

II-11Chiara Fornari

Development of a haematopoiesis systems pharmacology model for prediction of carboplatin induced bone marrow toxicity

Wednesday 15:50-17:20

II-25

Integrated novel modelling framework for evaluating the efficacy and cost effectiveness of novel pharmaceutical agents in stroke prevention

Wednesday 15:50-17:20

II-32Kosalaram Goteti

Drug-disease model describing the effect of intraarticular injected sprifermin on cartilage thickness measured by magnetic resonance imaging in osteoarthritis patients

Wednesday 15:50-17:20

II-36Hans Peter Grimm

PK Projections for Therapeutic Proteins in Entry Into Human Studies: Roche pRED Experience From 2004 to 2016

Wednesday 15:50-17:20

II-37Ana-Marija Grisic

Towards a comprehensive PK/PD model of infliximab in inflammatory bowel diseases, with support of prior knowledge

Wednesday 15:50-17:20

II-40Emilie Hénin

Individual therapeutic monitoring strategy of a factor IX concentrate (OCTAFIX ®) for prophylaxis in patients with haemophilia B, using population modelling approaches

Wednesday 15:50-17:20

II-42Eef Hoeben

Modelling the Transfer of Sildenafil Across the Placenta with Data of an Ex-Vivo Human Placenta Perfusion Experiment

Wednesday 15:50-17:20

II-43Nick Holford

Using Biomarkers to Predict the Target Dose of Warfarin and Linezolid

Wednesday 15:50-17:20

II-54Petra Jauslin

Population Pharmacokinetic Analysis of Tildrakizumab, an Anti-IL-23 Antibody, in Healthy Volunteers and Subjects with Psoriasis

Wednesday 15:50-17:20

II-55Garrit Jentsch

A repeated time-to-event model is superior to a count regression analysis in linking FVIII activity to bleeding events in prophylactically treated patients with severe haemophilia A

Wednesday 15:50-17:20

II-58Koen Jolling

Population pharmacokinetic modelling of CHF6001 following dry powder inhalation in healthy volunteers.

Wednesday 15:50-17:20

II-59Fredrik Jonsson

Exposure-Response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients

Wednesday 15:50-17:20

II-72Hyungsub Kim

Pharmacokinetic and pharmacodynamic modeling of 10% intravenous immunoglobulin and glucocorticoids for adult patients with immune thrombocytopenia

Wednesday 15:50-17:20

III-08Magnus Åstrand

Longitudinal pharmacometric modelling of serum potassium lowering effect of sodium zirconium cyclosilicate in patients with hyperkalemia

Thursday 09:55-11:30

III-19Carla Bastida Fernández

PK/PD of the individual components of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment.

Thursday 09:55-11:30

III-21Amina Bensalem

Concentration-effect relationships of therapeutic monoclonal antibody rituximab in rheumatoid arthritis.

Thursday 09:55-11:30

III-26Alessandro Boianelli

A quantitative systems pharmacology model for understanding the role of dietary fructose metabolism in NAFLD

Thursday 09:55-11:30

III-27Charlotte Bon

Capacity limits of ASGPR mediated liver targeting

Thursday 09:55-11:30

III-35Wonkyung Byon

Apixaban for treatment of venous thromboembolism (VTEtx): Use of Model-Based Meta-Analysis (MBMA) to support Phase 3 dose selection and beyond

Thursday 09:55-11:30

III-38Marc Cerou

HAM-D score analysis of patients under placebo with major depressive disorder using item response theory

Thursday 09:55-11:30

III-40Dong Woo Chae

Predictive Modeling of PCA Effect on Postoperative Pain Management

Thursday 09:55-11:30

III-63Nico de Jager

Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate® P (Humate P) in patients diagnosed with von Willebrands Disease.

Thursday 09:55-11:30

III-74Erwin Dreesen

Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of infliximab induction therapy on mucosal healing in patients with ulcerative colitis

Thursday 09:55-11:30

III-77Salvatore D'Agate

Development of a drug-disease model describing individual IPSS trajectories in BPH patients: Implication of disease progression and covariate factors on long term treatment response

Thursday 09:55-11:30

IV-02Shankar Lanke

Population Pharmacokinetic Analyses of Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease

Thursday 15:10-16:40

IV-13Rasmus Jansson Löfmark

Pharmacokinetic population modelling of a GLP1 beta cell targeting oligonucleotide

Thursday 15:10-16:40

IV-15Qiang Lu

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma

Thursday 15:10-16:40

IV-18Lei Ma

Efpeglenatide dose selection for a phase 3 study in type 2 diabetes mellitus (T2DM) patients: pharmacokinetics and pharmacodynamics (PK/PD) modeling, network meta-analysis and clinical trial simulation

Thursday 15:10-16:40

IV-19Matthias Machacek

A Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood

Thursday 15:10-16:40

IV-43Boram Ohk

Population pharmacokinetics of sumatriptan in healthy korean subjects : sex differences

Thursday 15:10-16:40

IV-53Christophe Passot

Therapeutic drug monitoring of eculizumab in atypical hemolytic uremic syndrome

Thursday 15:10-16:40

IV-64Jens Przybilla

Epigenetic modelling of DNA demethylation therapy in Acute Myeloid Leukemia

Thursday 15:10-16:40

IV-66Luis Quintairos Domenech

Pharmacodynamic modelling of biomarkers in kidney transplantation: a transformed binary data population approach

Thursday 15:10-16:40

IV-69François Riglet

Multiple response modelling of mycophenolic acid pharmacokinetics in adult patients with transplanted kidneys by population approach

Thursday 15:10-16:40

IV-72Leire Ruiz Cerdá

External validation of Systems Pharmacology Models of the Coagulation Network with published data

Thursday 15:10-16:40

IV-76Stephan Schaller

Towards Predictions of Clinical Trial Outcomes: Combining PBPK and QSP within a Translational Diabetes Disease Platform

Thursday 15:10-16:40